416 related articles for article (PubMed ID: 12464356)
1. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
[TBL] [Abstract][Full Text] [Related]
2. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
[TBL] [Abstract][Full Text] [Related]
3. [2-(O-Phenylalkyl)phenoxy]alkylamines III: Synthesis and selective serotonin-2 receptor binding (2).
Tanaka N; Goto R; Ito R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
Chem Pharm Bull (Tokyo); 2000 Nov; 48(11):1729-39. PubMed ID: 11086903
[TBL] [Abstract][Full Text] [Related]
4. Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis.
Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Fukushige J; Tani Y; Asai F
Eur J Pharmacol; 2005 Oct; 521(1-3):156-63. PubMed ID: 16183055
[TBL] [Abstract][Full Text] [Related]
5. Gamma-mangostin, a novel type of 5-hydroxytryptamine 2A receptor antagonist.
Chairungsrilerd N; Furukawa KI; Ohta T; Nozoe S; Ohizumi Y
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):25-31. PubMed ID: 9459569
[TBL] [Abstract][Full Text] [Related]
6. Hypotensive and antiaggregative effects of eugenosedin-B with serotonin and alpha/beta-adrenoceptor antagonistic activities in rats and human platelets.
Shen KP; Chu LW; Hsieh SL; An LM; Chen IJ; Wu BN
J Cardiovasc Pharmacol; 2008 Feb; 51(2):154-61. PubMed ID: 18287883
[TBL] [Abstract][Full Text] [Related]
7. Anti-aggregation effect of aroxyalkyl derivatives of 2-methoxyphenylpiperazine is due to their 5-HT
Kubacka M; Kazek G; Kotańska M; Filipek B; Waszkielewicz AM; Mogilski S
Eur J Pharmacol; 2018 Jan; 818():263-270. PubMed ID: 29111111
[TBL] [Abstract][Full Text] [Related]
8. AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats.
Kihara H; Hirose K; Koganei H; Sasaki N; Yamamoto H; Kimura A; Nishimori T; Shoji M; Yoshimoto R
J Cardiovasc Pharmacol; 2000 Apr; 35(4):523-30. PubMed ID: 10774780
[TBL] [Abstract][Full Text] [Related]
9. Effects of R-102444, an orally active 5-HT2A receptor antagonist, in rat models of peripheral vascular disease.
Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
Vascul Pharmacol; 2004 Feb; 41(1):7-13. PubMed ID: 15135326
[TBL] [Abstract][Full Text] [Related]
10. AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels.
Barrett RJ; Appell KC; Kilpatrick BF; Proakis AG; Nolan JC; Walsh DA
J Cardiovasc Pharmacol; 1991 Jan; 17(1):41-53. PubMed ID: 1708055
[TBL] [Abstract][Full Text] [Related]
11. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
[TBL] [Abstract][Full Text] [Related]
12. [2-(omega-phenylalkyl)phenoxy]alkylamines.II: Synthesis and selective serotonin-2 receptor binding.
Tanaka N; Goto R; Ito R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
Chem Pharm Bull (Tokyo); 2000 Feb; 48(2):245-55. PubMed ID: 10705513
[TBL] [Abstract][Full Text] [Related]
13. Involvement of 5-HT(1B/1D) and 5-HT2A receptors in 5-HT-induced contraction of endothelium-denuded rabbit epicardial coronary arteries.
Ellwood AJ; Curtis MJ
Br J Pharmacol; 1997 Nov; 122(5):875-84. PubMed ID: 9384503
[TBL] [Abstract][Full Text] [Related]
14. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist.
Hara H; Osakabe M; Kitajima A; Tamao Y; Kikumoto R
Thromb Haemost; 1991 Apr; 65(4):415-20. PubMed ID: 2057925
[TBL] [Abstract][Full Text] [Related]
15. Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets.
Ogawa T; Sugidachi A; Asai F; Koike H
Blood Coagul Fibrinolysis; 1998 Apr; 9(3):233-40. PubMed ID: 9663705
[TBL] [Abstract][Full Text] [Related]
16. The involvement of 5-HT2-receptor sites in the activation of cat platelets.
De Clerck F; Xhonneux B; Leysen J; Janssen PA
Thromb Res; 1984 Feb; 33(3):305-21. PubMed ID: 6710435
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the contractile 5-hydroxytryptamine receptor in the renal artery of the normotensive rat.
Watts SW; Thompson JM
J Pharmacol Exp Ther; 2004 Apr; 309(1):165-72. PubMed ID: 14724222
[TBL] [Abstract][Full Text] [Related]
18. LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis.
Cohen ML; Robertson DW; Bloomquist WE; Wilson HC
J Pharmacol Exp Ther; 1992 Apr; 261(1):202-8. PubMed ID: 1560366
[TBL] [Abstract][Full Text] [Related]
19. Characterization of rat platelet serotonin receptors with tryptamine agonists and the antagonists: ketanserin and SCH 23390.
Killam AL; Cohen ML
Thromb Res; 1991 Nov; 64(3):331-40. PubMed ID: 1805448
[TBL] [Abstract][Full Text] [Related]
20. Serotonin receptors in rat jugular vein: presence and involvement in the contraction.
Linder AE; Gaskell GL; Szasz T; Thompson JM; Watts SW
J Pharmacol Exp Ther; 2010 Jul; 334(1):116-23. PubMed ID: 20378714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
